,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMaz2AF'}, 'Id': 'a0POZ00000CvMaz2AF', 'Event_Date__c': '2019-08-02', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000ArhmQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Awaiting registration with Medsafe.', 'fs': 'Awaiting registration with Medsafe.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb02AF'}, 'Id': 'a0POZ00000CvMb02AF', 'Event_Date__c': '2020-05-26', 'Event_Description__c': 'Awaiting registration with Medsafe.', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BnEVQA0'}, 'change': None}]",Aug 2019,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2020', 'fs': 'Aug 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb12AF'}, 'Id': 'a0POZ00000CvMb12AF', 'Event_Date__c': '2020-08-27', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2020', 'Status_History__c': 'a132P000000C59aQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Anti-Infective Subcommittee meeting to provide advice on Tuesday 22 September 2020', 'fs': 'Assigned to Anti-Infective Subcommittee meeting to provide advice on Tuesday 22 September 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb22AF'}, 'Id': 'a0POZ00000CvMb22AF', 'Event_Date__c': '2020-09-15', 'Event_Description__c': 'Assigned to Anti-Infective Subcommittee meeting to provide advice on Tuesday 22 September 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000Cg8iQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that letermovir for cytomegalovirus infection prophylaxis in haematopoietic stem cell transplant patients be listed with a <b>low priority</b> within the context of treatments for infections, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt; color: black;"">Special Authority for Subsidy</b></p><p><span style=""font-size: 9pt;"">Initial application only from a haematologist or infectious disease specialist; approvals valid for four months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1\xa0\xa0\xa0Patient must have undergone an allogeneic haematopoietic stem cell transplant; and</span></p><p><span style=""font-size: 9pt;"">2\xa0\xa0\xa0The patient must have confirmed presence of cytomegalovirus-specific antibodies; and </span></p><p><span style=""font-size: 9pt;"">3\xa0\xa0\xa0Treatment must commence within 28 days of an allogeneic haematopoietic stem cell transplant; and</span></p><p><span style=""font-size: 9pt;"">4</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Maximum treatment duration of one hundred days.</span></p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to:</p><p>5.2.1.<span style=""font-size: 7pt;""> </span>The high health need of patients who develop cytomegalovirus disease following allogenic haematopoietic stem cell transplant;</p><p>5.2.2.<span style=""font-size: 7pt;""> </span>Evidence that demonstrates that letermovir reduces cytomegalovirus infection, which has the potential decrease the use of pre-emptive therapy (PET);</p><p>5.2.3.<span style=""font-size: 7pt;""> </span>The lack of evidence of significant difference in mortality between letermovir and placebo in this setting.\xa0\xa0</p>', 'fs': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that letermovir for cytomegalovirus infection prophylaxis in haematopoietic stem cell transplant patients be listed with a <b>low priority</b> within the context of treatments for infections, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt; color: black;"">Special Authority for Subsidy</b></p><p><span style=""font-size: 9pt;"">Initial application only from a haematologist or infectious disease specialist; approvals valid for four months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1\xa0\xa0\xa0Patient must have undergone an allogeneic haematopoietic stem cell transplant; and</span></p><p><span style=""font-size: 9pt;"">2\xa0\xa0\xa0The patient must have confirmed presence of cytomegalovirus-specific antibodies; and </span></p><p><span style=""font-size: 9pt;"">3\xa0\xa0\xa0Treatment must commence within 28 days of an allogeneic haematopoietic stem cell transplant; and</span></p><p><span style=""font-size: 9pt;"">4</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Maximum treatment duration of one hundred days.</span></p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to:</p><p>5.2.1.<span style=""font-size: 7pt;""> </span>The high health need of patients who develop cytomegalovirus disease following allogenic haematopoietic stem cell transplant;</p><p>5.2.2.<span style=""font-size: 7pt;""> </span>Evidence that demonstrates that letermovir reduces cytomegalovirus infection, which has the potential decrease the use of pre-emptive therapy (PET);</p><p>5.2.3.<span style=""font-size: 7pt;""> </span>The lack of evidence of significant difference in mortality between letermovir and placebo in this setting.\xa0\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that following initial infection, cytomegalovirus establishes a life-long latent infection in the host and is usually asymptomatic. The Subcommittee noted that patients who have undergone allogeneic haematopoietic stem cell transplant are heavily immunocompromised, which can result in cytomegalovirus reactivation (in cytomegalovirus seropositive patients) or cytomegalovirus arising de novo (if cytomegalovirus seronegative), and either way may lead to severe cytomegalovirus disease.</p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the highest risk for cytomegalovirus infection and cytomegalovirus disease has been reported for haematopoietic stem cells transplant patients who are cytomegalovirus seropositive, regardless of donor serostatus (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840099/"" target=""_blank"">Styczynski. Infect Dis Ther. 2018;7:1-16</a>). The Subcommittee noted that the risk of developing cytomegalovirus infection is the greatest in the first 100 days post-transplant (<a href=""https://pubmed.ncbi.nlm.nih.gov/26722656/"" target=""_blank"">Bhat et al. World J Transplant. 2015;5:287-91</a>).</p><p><br></p><p>5.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that cytomegalovirus reactivation has been reported in up to 60-80% of patients with positive cytomegalovirus serology who have undergone allogeneic haematopoietic stem cell transplants, with approximately one-third of these patients going on to develop symptomatic cytomegalovirus disease (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358229"" target=""_blank"">Pollack et al. Biol Blood Marrow Transplant. 2011;17:664-73</a>). The Subcommittee noted that cytomegalovirus disease has direct effects on various systems, which can result in end-organ disease,<sup> </sup>most commonly manifesting as pneumonia and gastrointestinal disease (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496754/"" target=""_blank"">Azevedo et al. Clinics. 2015;70:515-23</a>). The Subcommittee noted that cytomegalovirus disease may also have indirect but other severe effects, such as increased incidence of Graft vs host disease (GvHD) and increased risk of serious bacterial and fungal infections, mediated by the pro-inflammatory and immunosuppressive properties of cytomegalovirus <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556539/"" target=""_blank"">(Helou &amp; Razonable. Infec Drug Resist. 2019;12:1481-91</a>).</p><p><br></p><p>5.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the development of cytomegalovirus viraemia is associated with poorer survival outcomes following allogeneic haematopoietic stem cell transplant, and that for cytomegalovirus seropositive patients any level of cytomegalovirus viraemia, including asymptomatic, low level infection, has been associated with an increased risk of overall mortality and morbidity (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914379/"" target=""_blank"">Green et al. Lancet Haematol. 2016;3:e119-27</a>). The Subcommittee noted that lung infiltration of cytomegalovirus carries a 50% mortality.</p><p><br></p><p>5.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that currently patients who have undergone haematopoietic stem cell transplant have their viral load monitored weekly, and if evidence of viral replication is detected, a pre-emptive therapy (PET) approach is taken using either intravenous ganciclovir or oral valganciclovir. The Subcommittee noted that foscarnet is available as second-line PET for patients ineligible for, intolerant or resistant to ganciclovir/ valganciclovir.</p><p><br></p><p>5.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in 2017, 104 allogeneic haematopoietic stem cell transplants were performed in New Zealand, and 86% of these patients were aged over 15 years (<a href=""https://www.abmtrr.org/"" target=""_blank"">ABMTRR. 2018</a>). The Subcommittee considered that the haematopoietic stem cell transplant population appears to be relatively consistent over time.</p><p><br></p><p>5.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a study of cytomegalovirus seroprevalence of New Zealand blood donors indicated cytomegalovirus seropositivity increases with age, and that 93.3% of Pacific Islander donors, 80.4% of Māori donors, 77.6% of Asian donors and 54.9% of Caucasian donors were cytomegalovirus seropositive (<a href=""https://www.cambridge.org/core/services/aop-cambridge-core/content/view/28158FE7136D50F59CBAD75767F3661D/S0950268809990094a.pdf/cytomegalovirus_seroprevalence_and_cytomegalovirussafe_seropositive_blood_donors.pdf"" target=""_blank"">Badami et al. Epidemiol Infect. 2009;137:1776-80</a>).</p><p><br></p><p>5.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that letermovir inhibits the cytomegalovirus DNA terminase complex, required for viral replication, and in turn affects the formation of proper unit length genomes and interferes with virion maturation.</p><p><br></p><p>5.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the recommended dose of letermovir is 240 mg once daily when used concurrently with ciclosporin or 480 mg once daily if not used with ciclosporin.</p><p><br></p><p>5.10.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of the P001 phase III, double-blind, placebo-controlled randomised trial investigating letermovir compared with placebo as prophylaxis for patients ≥18 years undergoing allogeneic haematopoietic stem cell transplant who were cytomegalovirus-seropositive and had an undetectable level of cytomegalovirus DNA (<a href=""https://pubmed.ncbi.nlm.nih.gov/29211658/"" target=""_blank"">Marty et al. N Engl J Med. 2017. 21;377:2433-44</a>). The Subcommittee noted that clinically significant cytomegalovirus infection through week 24 was reported in 37.5% of the letermovir group compared with 60.6% placebo (CMV risk stratum-adjusted absolute difference -23.5%, 95% confidence interval (CI) -32.5 to -14.6, p&lt;0.001). The Committee noted that at week 48, there was no statistically significant difference in all-cause mortality between groups, 20.9% letermovir compared with 25.5% placebo (p=0.12). The Subcommittee noted that there were no statistically significant differences in adverse events reported. The Subcommittee considered that the trial was well designed and demonstrated a good comparison of letermovir to placebo.</p><p><br></p><p>5.11.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of a post-hoc analysis of the P001 trial that investigated the effect of letermovir on all-cause mortality in patients (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146004/"" target=""_blank"">Ljungman et al. Clin Infect. Dis. 2020;70:1525-33</a>). The Subcommittee noted the hazard ratio (HR) for all-cause mortality at week 24 post-transplant for letermovir compared to placebo as 0.58 (95% CI: 0.35-0.98; p=0.04), however at week 48, there was no statistically significant difference observed (HR 0.74, 95% CI: 0.49–1.11; p=0.14). The Subcommittee noted that the incidence of all-cause mortality through week 48 post-haematopoietic stem cell transplant in the letermovir group was similar in patients with or without clinically significant cytomegalovirus infection (15.8% vs 19.4%; p=0.71). The Subcommittee noted that for patients who developed clinically significant cytomegalovirus infection, the HR for all-cause mortality was 0.45 (95% confidence interval, 0.21–1.00; p=0.05) at week 48 for letermovir compared with placebo.</p><p><br></p><p>5.12.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of a dose-determining study (<a href=""https://pubmed.ncbi.nlm.nih.gov/24806159/"" target=""_blank"">Chemaly et al. N Eng J Med. 2014;370:1781-9</a>). The Subcommittee noted that the incidence of prophylaxis failure was 29% for the 240 mg letermovir group compared with 64% for the placebo group (p=0.007). The Subcommittee noted that this dose had the lowest prophylaxis failure out of all doses investigated.</p><p><br></p><p>5.13.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that letermovir is not registered for use in people under 18 years of age and there is a lack for data of letermovir use in this population. The Subcommittee considered that haematopoietic stem cell transplants are protocolised and if letermovir were to be funded and incorporated into standardised protocol, it is likely that eligible patients under 18 years may also receive letermovir in this setting. The Subcommittee considered that there was little clinical basis for any Special Authority restrictions for letermovir to restrict by age.</p><p><br></p><p>5.14.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that currently patients do not routinely receive antiviral CMV prophylaxis following allogeneic haematopoietic stem cell transplant in New Zealand, and therefore the comparator would be placebo.</p><p><br></p><p>5.15.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee considered that if letermovir were funded and incorporated into allogenic haematopoietic stem cell transplant protocol, uptake would be 95-100%, with only patients contraindicated not being offered and consenting to receive letermovir.</p><p><br></p><p>5.16.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee considered that PET has associated toxicities, and any reduction in PET use would be of benefit both clinically and financially. The Subcommittee considered that the supplier’s PET cost-estimates appeared to be outdated.</p><p>5.17.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that ciclosporin is often used post-transplant to prevent GvHD and considered that the supplier’s estimate that 95% of patients would be prescribed ciclosporin and thus receive a lower dose of 240 mg letermovir was reasonable.</p><p>5.18.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted letermovir is available as both oral and injection for infusion formulations and considered the assumption that 95% of patients would use the oral formulation was reasonable.\xa0</p>', 'fs': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that following initial infection, cytomegalovirus establishes a life-long latent infection in the host and is usually asymptomatic. The Subcommittee noted that patients who have undergone allogeneic haematopoietic stem cell transplant are heavily immunocompromised, which can result in cytomegalovirus reactivation (in cytomegalovirus seropositive patients) or cytomegalovirus arising de novo (if cytomegalovirus seronegative), and either way may lead to severe cytomegalovirus disease.</p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the highest risk for cytomegalovirus infection and cytomegalovirus disease has been reported for haematopoietic stem cells transplant patients who are cytomegalovirus seropositive, regardless of donor serostatus (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840099/"" target=""_blank"">Styczynski. Infect Dis Ther. 2018;7:1-16</a>). The Subcommittee noted that the risk of developing cytomegalovirus infection is the greatest in the first 100 days post-transplant (<a href=""https://pubmed.ncbi.nlm.nih.gov/26722656/"" target=""_blank"">Bhat et al. World J Transplant. 2015;5:287-91</a>).</p><p><br></p><p>5.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that cytomegalovirus reactivation has been reported in up to 60-80% of patients with positive cytomegalovirus serology who have undergone allogeneic haematopoietic stem cell transplants, with approximately one-third of these patients going on to develop symptomatic cytomegalovirus disease (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358229"" target=""_blank"">Pollack et al. Biol Blood Marrow Transplant. 2011;17:664-73</a>). The Subcommittee noted that cytomegalovirus disease has direct effects on various systems, which can result in end-organ disease,<sup> </sup>most commonly manifesting as pneumonia and gastrointestinal disease (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496754/"" target=""_blank"">Azevedo et al. Clinics. 2015;70:515-23</a>). The Subcommittee noted that cytomegalovirus disease may also have indirect but other severe effects, such as increased incidence of Graft vs host disease (GvHD) and increased risk of serious bacterial and fungal infections, mediated by the pro-inflammatory and immunosuppressive properties of cytomegalovirus <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556539/"" target=""_blank"">(Helou &amp; Razonable. Infec Drug Resist. 2019;12:1481-91</a>).</p><p><br></p><p>5.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the development of cytomegalovirus viraemia is associated with poorer survival outcomes following allogeneic haematopoietic stem cell transplant, and that for cytomegalovirus seropositive patients any level of cytomegalovirus viraemia, including asymptomatic, low level infection, has been associated with an increased risk of overall mortality and morbidity (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914379/"" target=""_blank"">Green et al. Lancet Haematol. 2016;3:e119-27</a>). The Subcommittee noted that lung infiltration of cytomegalovirus carries a 50% mortality.</p><p><br></p><p>5.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that currently patients who have undergone haematopoietic stem cell transplant have their viral load monitored weekly, and if evidence of viral replication is detected, a pre-emptive therapy (PET) approach is taken using either intravenous ganciclovir or oral valganciclovir. The Subcommittee noted that foscarnet is available as second-line PET for patients ineligible for, intolerant or resistant to ganciclovir/ valganciclovir.</p><p><br></p><p>5.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in 2017, 104 allogeneic haematopoietic stem cell transplants were performed in New Zealand, and 86% of these patients were aged over 15 years (<a href=""https://www.abmtrr.org/"" target=""_blank"">ABMTRR. 2018</a>). The Subcommittee considered that the haematopoietic stem cell transplant population appears to be relatively consistent over time.</p><p><br></p><p>5.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a study of cytomegalovirus seroprevalence of New Zealand blood donors indicated cytomegalovirus seropositivity increases with age, and that 93.3% of Pacific Islander donors, 80.4% of Māori donors, 77.6% of Asian donors and 54.9% of Caucasian donors were cytomegalovirus seropositive (<a href=""https://www.cambridge.org/core/services/aop-cambridge-core/content/view/28158FE7136D50F59CBAD75767F3661D/S0950268809990094a.pdf/cytomegalovirus_seroprevalence_and_cytomegalovirussafe_seropositive_blood_donors.pdf"" target=""_blank"">Badami et al. Epidemiol Infect. 2009;137:1776-80</a>).</p><p><br></p><p>5.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that letermovir inhibits the cytomegalovirus DNA terminase complex, required for viral replication, and in turn affects the formation of proper unit length genomes and interferes with virion maturation.</p><p><br></p><p>5.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the recommended dose of letermovir is 240 mg once daily when used concurrently with ciclosporin or 480 mg once daily if not used with ciclosporin.</p><p><br></p><p>5.10.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of the P001 phase III, double-blind, placebo-controlled randomised trial investigating letermovir compared with placebo as prophylaxis for patients ≥18 years undergoing allogeneic haematopoietic stem cell transplant who were cytomegalovirus-seropositive and had an undetectable level of cytomegalovirus DNA (<a href=""https://pubmed.ncbi.nlm.nih.gov/29211658/"" target=""_blank"">Marty et al. N Engl J Med. 2017. 21;377:2433-44</a>). The Subcommittee noted that clinically significant cytomegalovirus infection through week 24 was reported in 37.5% of the letermovir group compared with 60.6% placebo (CMV risk stratum-adjusted absolute difference -23.5%, 95% confidence interval (CI) -32.5 to -14.6, p&lt;0.001). The Committee noted that at week 48, there was no statistically significant difference in all-cause mortality between groups, 20.9% letermovir compared with 25.5% placebo (p=0.12). The Subcommittee noted that there were no statistically significant differences in adverse events reported. The Subcommittee considered that the trial was well designed and demonstrated a good comparison of letermovir to placebo.</p><p><br></p><p>5.11.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of a post-hoc analysis of the P001 trial that investigated the effect of letermovir on all-cause mortality in patients (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146004/"" target=""_blank"">Ljungman et al. Clin Infect. Dis. 2020;70:1525-33</a>). The Subcommittee noted the hazard ratio (HR) for all-cause mortality at week 24 post-transplant for letermovir compared to placebo as 0.58 (95% CI: 0.35-0.98; p=0.04), however at week 48, there was no statistically significant difference observed (HR 0.74, 95% CI: 0.49–1.11; p=0.14). The Subcommittee noted that the incidence of all-cause mortality through week 48 post-haematopoietic stem cell transplant in the letermovir group was similar in patients with or without clinically significant cytomegalovirus infection (15.8% vs 19.4%; p=0.71). The Subcommittee noted that for patients who developed clinically significant cytomegalovirus infection, the HR for all-cause mortality was 0.45 (95% confidence interval, 0.21–1.00; p=0.05) at week 48 for letermovir compared with placebo.</p><p><br></p><p>5.12.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of a dose-determining study (<a href=""https://pubmed.ncbi.nlm.nih.gov/24806159/"" target=""_blank"">Chemaly et al. N Eng J Med. 2014;370:1781-9</a>). The Subcommittee noted that the incidence of prophylaxis failure was 29% for the 240 mg letermovir group compared with 64% for the placebo group (p=0.007). The Subcommittee noted that this dose had the lowest prophylaxis failure out of all doses investigated.</p><p><br></p><p>5.13.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that letermovir is not registered for use in people under 18 years of age and there is a lack for data of letermovir use in this population. The Subcommittee considered that haematopoietic stem cell transplants are protocolised and if letermovir were to be funded and incorporated into standardised protocol, it is likely that eligible patients under 18 years may also receive letermovir in this setting. The Subcommittee considered that there was little clinical basis for any Special Authority restrictions for letermovir to restrict by age.</p><p><br></p><p>5.14.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that currently patients do not routinely receive antiviral CMV prophylaxis following allogeneic haematopoietic stem cell transplant in New Zealand, and therefore the comparator would be placebo.</p><p><br></p><p>5.15.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee considered that if letermovir were funded and incorporated into allogenic haematopoietic stem cell transplant protocol, uptake would be 95-100%, with only patients contraindicated not being offered and consenting to receive letermovir.</p><p><br></p><p>5.16.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee considered that PET has associated toxicities, and any reduction in PET use would be of benefit both clinically and financially. The Subcommittee considered that the supplier’s PET cost-estimates appeared to be outdated.</p><p>5.17.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that ciclosporin is often used post-transplant to prevent GvHD and considered that the supplier’s estimate that 95% of patients would be prescribed ciclosporin and thus receive a lower dose of 240 mg letermovir was reasonable.</p><p>5.18.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted letermovir is available as both oral and injection for infusion formulations and considered the assumption that 95% of patients would use the oral formulation was reasonable.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for letermovir for cytomegalovirus infection prophylaxis in allogenic haematopoietic stem cell transplant patients.</p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for letermovir for cytomegalovirus infection prophylaxis in allogenic haematopoietic stem cell transplant patients.</p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regard to item 8, letermovir for cytomegalovirus infection prophylaxis:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that the application be referred to the Transplant Immunosuppressant Subcommittee for review. </p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted it would consider the Transplant Immunosuppressant Subcommittee’s record prior to noting or agreeing with any recommendation for the application. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted and <b>agreed</b> with the Anti-infective Subcommittee’s recorded considerations and recommendations regarding the remaining items of the September 2020 meeting.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regard to item 8, letermovir for cytomegalovirus infection prophylaxis:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that the application be referred to the Transplant Immunosuppressant Subcommittee for review. </p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted it would consider the Transplant Immunosuppressant Subcommittee’s record prior to noting or agreeing with any recommendation for the application. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted and <b>agreed</b> with the Anti-infective Subcommittee’s recorded considerations and recommendations regarding the remaining items of the September 2020 meeting.\xa0</p>', 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Anti-Infective Subcommittee at meeting Tuesday 22 September 2020.', 'fs': 'Clinical advice received from Anti-Infective Subcommittee at meeting Tuesday 22 September 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb32AF'}, 'Id': 'a0POZ00000CvMb32AF', 'Event_Date__c': '2021-03-18', 'Event_Description__c': 'Clinical advice received from Anti-Infective Subcommittee at meeting Tuesday 22 September 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Low', 'Formatted_Date__c': 'Mar 2021', 'Published_Recommendation__c': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that letermovir for cytomegalovirus infection prophylaxis in haematopoietic stem cell transplant patients be listed with a <b>low priority</b> within the context of treatments for infections, subject to the following Special Authority criteria:</p><p><b style=""font-size: 9pt; color: black;"">Special Authority for Subsidy</b></p><p><span style=""font-size: 9pt;"">Initial application only from a haematologist or infectious disease specialist; approvals valid for four months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">All of the following:</span></p><p><span style=""font-size: 9pt;"">1\xa0\xa0\xa0Patient must have undergone an allogeneic haematopoietic stem cell transplant; and</span></p><p><span style=""font-size: 9pt;"">2\xa0\xa0\xa0The patient must have confirmed presence of cytomegalovirus-specific antibodies; and </span></p><p><span style=""font-size: 9pt;"">3\xa0\xa0\xa0Treatment must commence within 28 days of an allogeneic haematopoietic stem cell transplant; and</span></p><p><span style=""font-size: 9pt;"">4</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Maximum treatment duration of one hundred days.</span></p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to:</p><p>5.2.1.<span style=""font-size: 7pt;""> </span>The high health need of patients who develop cytomegalovirus disease following allogenic haematopoietic stem cell transplant;</p><p>5.2.2.<span style=""font-size: 7pt;""> </span>Evidence that demonstrates that letermovir reduces cytomegalovirus infection, which has the potential decrease the use of pre-emptive therapy (PET);</p><p>5.2.3.<span style=""font-size: 7pt;""> </span>The lack of evidence of significant difference in mortality between letermovir and placebo in this setting.\xa0\xa0</p>', 'Published_Application__c': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for letermovir for cytomegalovirus infection prophylaxis in allogenic haematopoietic stem cell transplant patients.</p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>5.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that following initial infection, cytomegalovirus establishes a life-long latent infection in the host and is usually asymptomatic. The Subcommittee noted that patients who have undergone allogeneic haematopoietic stem cell transplant are heavily immunocompromised, which can result in cytomegalovirus reactivation (in cytomegalovirus seropositive patients) or cytomegalovirus arising de novo (if cytomegalovirus seronegative), and either way may lead to severe cytomegalovirus disease.</p><p><br></p><p>5.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the highest risk for cytomegalovirus infection and cytomegalovirus disease has been reported for haematopoietic stem cells transplant patients who are cytomegalovirus seropositive, regardless of donor serostatus (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840099/"" target=""_blank"">Styczynski. Infect Dis Ther. 2018;7:1-16</a>). The Subcommittee noted that the risk of developing cytomegalovirus infection is the greatest in the first 100 days post-transplant (<a href=""https://pubmed.ncbi.nlm.nih.gov/26722656/"" target=""_blank"">Bhat et al. World J Transplant. 2015;5:287-91</a>).</p><p><br></p><p>5.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that cytomegalovirus reactivation has been reported in up to 60-80% of patients with positive cytomegalovirus serology who have undergone allogeneic haematopoietic stem cell transplants, with approximately one-third of these patients going on to develop symptomatic cytomegalovirus disease (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358229"" target=""_blank"">Pollack et al. Biol Blood Marrow Transplant. 2011;17:664-73</a>). The Subcommittee noted that cytomegalovirus disease has direct effects on various systems, which can result in end-organ disease,<sup> </sup>most commonly manifesting as pneumonia and gastrointestinal disease (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496754/"" target=""_blank"">Azevedo et al. Clinics. 2015;70:515-23</a>). The Subcommittee noted that cytomegalovirus disease may also have indirect but other severe effects, such as increased incidence of Graft vs host disease (GvHD) and increased risk of serious bacterial and fungal infections, mediated by the pro-inflammatory and immunosuppressive properties of cytomegalovirus <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556539/"" target=""_blank"">(Helou &amp; Razonable. Infec Drug Resist. 2019;12:1481-91</a>).</p><p><br></p><p>5.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the development of cytomegalovirus viraemia is associated with poorer survival outcomes following allogeneic haematopoietic stem cell transplant, and that for cytomegalovirus seropositive patients any level of cytomegalovirus viraemia, including asymptomatic, low level infection, has been associated with an increased risk of overall mortality and morbidity (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914379/"" target=""_blank"">Green et al. Lancet Haematol. 2016;3:e119-27</a>). The Subcommittee noted that lung infiltration of cytomegalovirus carries a 50% mortality.</p><p><br></p><p>5.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that currently patients who have undergone haematopoietic stem cell transplant have their viral load monitored weekly, and if evidence of viral replication is detected, a pre-emptive therapy (PET) approach is taken using either intravenous ganciclovir or oral valganciclovir. The Subcommittee noted that foscarnet is available as second-line PET for patients ineligible for, intolerant or resistant to ganciclovir/ valganciclovir.</p><p><br></p><p>5.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in 2017, 104 allogeneic haematopoietic stem cell transplants were performed in New Zealand, and 86% of these patients were aged over 15 years (<a href=""https://www.abmtrr.org/"" target=""_blank"">ABMTRR. 2018</a>). The Subcommittee considered that the haematopoietic stem cell transplant population appears to be relatively consistent over time.</p><p><br></p><p>5.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a study of cytomegalovirus seroprevalence of New Zealand blood donors indicated cytomegalovirus seropositivity increases with age, and that 93.3% of Pacific Islander donors, 80.4% of Māori donors, 77.6% of Asian donors and 54.9% of Caucasian donors were cytomegalovirus seropositive (<a href=""https://www.cambridge.org/core/services/aop-cambridge-core/content/view/28158FE7136D50F59CBAD75767F3661D/S0950268809990094a.pdf/cytomegalovirus_seroprevalence_and_cytomegalovirussafe_seropositive_blood_donors.pdf"" target=""_blank"">Badami et al. Epidemiol Infect. 2009;137:1776-80</a>).</p><p><br></p><p>5.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that letermovir inhibits the cytomegalovirus DNA terminase complex, required for viral replication, and in turn affects the formation of proper unit length genomes and interferes with virion maturation.</p><p><br></p><p>5.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the recommended dose of letermovir is 240 mg once daily when used concurrently with ciclosporin or 480 mg once daily if not used with ciclosporin.</p><p><br></p><p>5.10.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of the P001 phase III, double-blind, placebo-controlled randomised trial investigating letermovir compared with placebo as prophylaxis for patients ≥18 years undergoing allogeneic haematopoietic stem cell transplant who were cytomegalovirus-seropositive and had an undetectable level of cytomegalovirus DNA (<a href=""https://pubmed.ncbi.nlm.nih.gov/29211658/"" target=""_blank"">Marty et al. N Engl J Med. 2017. 21;377:2433-44</a>). The Subcommittee noted that clinically significant cytomegalovirus infection through week 24 was reported in 37.5% of the letermovir group compared with 60.6% placebo (CMV risk stratum-adjusted absolute difference -23.5%, 95% confidence interval (CI) -32.5 to -14.6, p&lt;0.001). The Committee noted that at week 48, there was no statistically significant difference in all-cause mortality between groups, 20.9% letermovir compared with 25.5% placebo (p=0.12). The Subcommittee noted that there were no statistically significant differences in adverse events reported. The Subcommittee considered that the trial was well designed and demonstrated a good comparison of letermovir to placebo.</p><p><br></p><p>5.11.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of a post-hoc analysis of the P001 trial that investigated the effect of letermovir on all-cause mortality in patients (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146004/"" target=""_blank"">Ljungman et al. Clin Infect. Dis. 2020;70:1525-33</a>). The Subcommittee noted the hazard ratio (HR) for all-cause mortality at week 24 post-transplant for letermovir compared to placebo as 0.58 (95% CI: 0.35-0.98; p=0.04), however at week 48, there was no statistically significant difference observed (HR 0.74, 95% CI: 0.49–1.11; p=0.14). The Subcommittee noted that the incidence of all-cause mortality through week 48 post-haematopoietic stem cell transplant in the letermovir group was similar in patients with or without clinically significant cytomegalovirus infection (15.8% vs 19.4%; p=0.71). The Subcommittee noted that for patients who developed clinically significant cytomegalovirus infection, the HR for all-cause mortality was 0.45 (95% confidence interval, 0.21–1.00; p=0.05) at week 48 for letermovir compared with placebo.</p><p><br></p><p>5.12.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted the results of a dose-determining study (<a href=""https://pubmed.ncbi.nlm.nih.gov/24806159/"" target=""_blank"">Chemaly et al. N Eng J Med. 2014;370:1781-9</a>). The Subcommittee noted that the incidence of prophylaxis failure was 29% for the 240 mg letermovir group compared with 64% for the placebo group (p=0.007). The Subcommittee noted that this dose had the lowest prophylaxis failure out of all doses investigated.</p><p><br></p><p>5.13.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that letermovir is not registered for use in people under 18 years of age and there is a lack for data of letermovir use in this population. The Subcommittee considered that haematopoietic stem cell transplants are protocolised and if letermovir were to be funded and incorporated into standardised protocol, it is likely that eligible patients under 18 years may also receive letermovir in this setting. The Subcommittee considered that there was little clinical basis for any Special Authority restrictions for letermovir to restrict by age.</p><p><br></p><p>5.14.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that currently patients do not routinely receive antiviral CMV prophylaxis following allogeneic haematopoietic stem cell transplant in New Zealand, and therefore the comparator would be placebo.</p><p><br></p><p>5.15.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee considered that if letermovir were funded and incorporated into allogenic haematopoietic stem cell transplant protocol, uptake would be 95-100%, with only patients contraindicated not being offered and consenting to receive letermovir.</p><p><br></p><p>5.16.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee considered that PET has associated toxicities, and any reduction in PET use would be of benefit both clinically and financially. The Subcommittee considered that the supplier’s PET cost-estimates appeared to be outdated.</p><p>5.17.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted that ciclosporin is often used post-transplant to prevent GvHD and considered that the supplier’s estimate that 95% of patients would be prescribed ciclosporin and thus receive a lower dose of 240 mg letermovir was reasonable.</p><p>5.18.<span style=""font-size: 7pt;"">\xa0</span>The Subcommittee noted letermovir is available as both oral and injection for infusion formulations and considered the assumption that 95% of patients would use the oral formulation was reasonable.\xa0</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regard to item 8, letermovir for cytomegalovirus infection prophylaxis:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee <b>recommended</b> that the application be referred to the Transplant Immunosuppressant Subcommittee for review. </p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted it would consider the Transplant Immunosuppressant Subcommittee’s record prior to noting or agreeing with any recommendation for the application. </p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted and <b>agreed</b> with the Anti-infective Subcommittee’s recorded considerations and recommendations regarding the remaining items of the September 2020 meeting.\xa0</p>', 'Status_History__c': 'a132P000000ChRcQAK'}, 'change': None}]",Aug 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb42AF'}, 'Id': 'a0POZ00000CvMb42AF', 'Event_Date__c': '2021-03-28', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CigPQAS'}, 'change': None}]",Mar 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2022', 'fs': 'Jun 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb52AF'}, 'Id': 'a0POZ00000CvMb52AF', 'Event_Date__c': '2022-06-02', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2022', 'Status_History__c': 'a132P000000DnYAQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2022', 'fs': 'Dec 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb62AF'}, 'Id': 'a0POZ00000CvMb62AF', 'Event_Date__c': '2022-12-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2022', 'Status_History__c': 'a132P000000ED9GQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb72AF'}, 'Id': 'a0POZ00000CvMb72AF', 'Event_Date__c': '2023-06-12', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2023', 'Status_History__c': 'a132P000000EOP8QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2024', 'fs': 'Jun 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb82AF'}, 'Id': 'a0POZ00000CvMb82AF', 'Event_Date__c': '2024-06-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2024', 'Status_History__c': 'a13OZ00000ArK4cYAF'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ00000CvMb92AF'}, 'Id': 'a0POZ00000CvMb92AF', 'Event_Date__c': '2024-09-25', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EbsnvYAB'}, 'change': None}]",Jun 2022,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
